Luye Pharma

Luye Pharma is one of the earliest Chinese pharmaceutical companies to conduct clinical trials in major international markets and achieve breakthrough progress. Founded in 1994, the company has production bases in Yantai, Beijing, Nanjing, Luzhou, and Misbach, Germany; R&D centers in China, the United States, and Europe; and branches in Hong Kong, Singapore, and Malaysia, with nearly 4,000 employees worldwide.

Luye Pharma is R&D-driven, focusing on innovation and internationalization, committed to the development and production of innovative drugs. Over 30 marketed products focus on high-incidence and high-growth therapeutic areas such as the central nervous system, anti-tumor, cardiovascular, digestive, and metabolic diseases, covering major global pharmaceutical markets including China, the United States, the EU, and Japan, while continuously developing high-growth emerging international markets. With innovation capability building as its core, the company has a professional team and an R&D system in line with international standards, achieving internationally advanced levels in new formulation technologies such as microspheres, liposomes, and transdermal drug delivery. It is also committed to strategic layout in advanced drug delivery technologies, novel antibodies, cell and gene therapy, and collaborates with global partners to develop innovative monoclonal antibody drugs, nucleic acid drugs, and next-generation CAR-T technologies.

The company has a rich pipeline, with multiple innovative formulations and drugs in different phases of registration clinical studies conducted by the U.S. FDA, achieving breakthrough progress. Based on global R&D, global manufacturing, and a global market perspective, Luye Pharma always provides customers with high-quality pharmaceutical products and professional services, and strives to become one of the world's top 50 international specialized pharmaceutical companies by 2025.